20 May, 2019
The Annual General Meeting resolved to establish the presented income statement and balance sheet. It was also resolved at the Annual General Meeting that no dividend would be paid for the financial year 2018.
The Board of Directors and the President were discharged from liability for the 2018 financial year.
Board, auditor and fees
Ola Chamber, Kristian Kierkegaard, Mattias Münnich and Fredrik Sjövall were re-elected as board members and Mikaela Bruhammar was newly elected. Fredrik Sjövall was re-elected as Chairman of the Board. It was resolved that the fee shall be SEK 150,000 to the Chairman of the Board and SEK 75,000 each to the other Board members.
Ernst & Young AB was elected to the auditing firm. Authorized public accountant Stefan Svensson will be the chief auditor. It was decided that remuneration to the auditor should be paid according to approved invoice.
Authorization for the Board to issue shares, convertibles or warrants
In accordance with the Board"s proposal, the Meeting resolved to authorize the Board of Directors, on one or more occasions before the next Annual General Meeting, with or without deviation from the shareholders" preferential rights, to decide on a new share issue or issue of convertibles or warrants. The issue may be made against cash payment, non-payment or set-off. The number of shares that may be issued, or, upon the issue of convertibles or warrants, additional after conversion or exercise, with the support of the authorization shall be limited to ten (10) percent of the number of shares outstanding at the time of this meeting.
Decision to change the seat
The Meeting resolved to amend the Articles of Association in such a way that the seat of the Board of Directors is changed from Huddinge municipality to the municipality of Lund.
Flemingsberg May 20, 2019
Ziccum AB (publ)
Board of Directors
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
Mob: +46 709 61 55 99
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.
This press release was submitted for publication 20 May, 2019.